Inactive Instrument
Guided Therapeutics Inc Share Price OTC Bulletin Board
Stocks
US40171F2048
Advanced Medical Equipment & Technology
OTC Markets Traded|
End-of-day quote
Other stock markets
|
||
| - USD | - |
|
| 16/06 | Guided Therapeutics Files Premarket Approval Application Clinical Report with FDA | CI |
| 15/05 | Guided Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 | CI |
| Market Cap | 2.9Cr 2.54Cr 2.36Cr 2.17Cr 4.1Cr 276.93Cr 4.19Cr 28Cr 11Cr 136.04Cr 11Cr 11Cr 470.41Cr | P/E 2024 |
-3x | P/E 2025 | -12.7x |
|---|---|---|---|---|---|
| Enterprise Value | 3.18Cr 2.8Cr 2.59Cr 2.38Cr 4.51Cr 304.43Cr 4.6Cr 31Cr 12Cr 149.55Cr 12Cr 12Cr 517.12Cr | EV / Sales 2024 |
1,649x | EV / Sales 2025 | 64.4x |
| Free-Float |
63.48% | Yield 2024 * |
-
| Yield 2025 | - |
| Manager | Title | Age | Since |
|---|---|---|---|
Mark Faupel
CEO | Chief Executive Officer | 70 | 06/03/2023 |
| Chief Tech/Sci/R&D Officer | 70 | 02/12/2010 |
| Director | Title | Age | Since |
|---|---|---|---|
Mark Faupel
BRD | Director/Board Member | 70 | 01/12/2016 |
John Imhoff
BRD | Director/Board Member | 76 | 10/04/2006 |
Michael James
CHM | Chairman | 67 | 01/10/2013 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
| +0.28% | +0.97% | +21.54% | +0.49% | 20TCr | ||
| +0.08% | -4.43% | -20.49% | +17.13% | 14TCr | ||
| +0.56% | +1.13% | -2.29% | -15.94% | 14TCr | ||
| -0.27% | -1.09% | -56.73% | -14.89% | 6.65TCr | ||
| -0.46% | -2.73% | +17.60% | -1.41% | 5.31TCr | ||
| +2.80% | +1.69% | -22.83% | -29.39% | 4.41TCr | ||
| -0.19% | +2.56% | +8.73% | +11.70% | 3.79TCr | ||
| -0.85% | -1.60% | +5.76% | +38.77% | 3.7TCr | ||
| +0.94% | -0.39% | -13.07% | -20.05% | 2.94TCr | ||
| Average | +0.41% | -0.75% | -6.87% | -1.51% | 8.32TCr | |
| Weighted average by Cap. | +0.44% | -0.83% | -3.67% | -1.01% |
| 2024 | 2025 | |
|---|---|---|
| Net sales | 7T 6.15T 5.7T 5.24T 9.91T 7L 10.12T 67.99T 26.59T 3L 26.28T 25.71T 11.37L | 8L 7L 6L 6L 10.86L 7.33Cr 11.09L 74.5L 29.14L 3.6Cr 28.8L 28.17L 12Cr |
| Net income | -24.17L -21.23L -19.69L -18.1L -34.21L -23Cr -34.94L -2.35Cr -91.82L -11Cr -90.75L -88.77L -39Cr | -31.96L -28.08L -26.03L -23.94L -45.23L -31Cr -46.2L -3.1Cr -1.21Cr -15Cr -1.2Cr -1.17Cr -52Cr |
| Net Debt | 17.71L 15.56L 14.43L 13.27L 25.06L 17Cr 25.6L 1.72Cr 67.28L 8.32Cr 66.5L 65.05L 29Cr | 28.76L 25.27L 23.43L 21.54L 40.7L 28Cr 41.58L 2.79Cr 1.09Cr 14Cr 1.08Cr 1.06Cr 47Cr |
Employees
-
Select your edition
All financial news and data tailored to specific country editions
















